T. Walsh

Epidemiology · Clinical Infectious Diseases · 2000–2019

A researcher in the Science corpus: 23 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 75 citations into it
• Cell Biology — 10 citations into it

Whom T. Walsh trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Amy S. Lee

Who trusts T. Walsh overall

1. M. Pfaller
2. Dennis L. Stevens

Papers from T. Walsh's perspective

Ordered by how strongly the researchers T. Walsh trusts endorse each paper. Same corpus, a different order for every researcher.

1. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (New England Journal of Medicine)
2. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. (New England Journal of Medicine)
3. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (New England Journal of Medicine)
4. Evidence based medicine: what it is and what it isn't
5. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (Clinical Infectious Diseases)
6. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (Clinical Infectious Diseases)
7. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
8. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (New England Journal of Medicine)
9. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. (Journal of Clinical Epidemiology)
10. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. (New England Journal of Medicine)

Their papers

• Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium (2019) — 925 citations
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016) — 3,436 citations
• Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016) — 1,198 citations
• Human Rhinoviruses (2013) — 601 citations
• Pathogenesis of mucormycosis. (2012) — 722 citations
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009) — 3,078 citations
• Infections Caused by Scedosporium spp (2008) — 732 citations
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008) — 2,622 citations
• Anidulafungin versus fluconazole for invasive candidiasis. (2007) — 861 citations
• Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. (2007) — 749 citations
• Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (2007) — 1,520 citations
• Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. (2005) — 675 citations
• The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. (2005) — 819 citations
• Epidemiology and outcome of zygomycosis: a review of 929 reported cases. (2005) — 2,922 citations
• Guidelines for treatment of candidiasis. (2004) — 1,413 citations
• Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004) — 638 citations
• Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. (2004) — 876 citations
• Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. (2004) — 702 citations
• Voriconazole treatment for less-common, emerging, or refractory fungal infections. (2003) — 671 citations
• Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (2002) — 951 citations